001     304506
005     20250914022702.0
024 7 _ |a 10.2967/jnumed.125.270115
|2 doi
024 7 _ |a pmid:40935608
|2 pmid
024 7 _ |a 0097-9058
|2 ISSN
024 7 _ |a 0022-3123
|2 ISSN
024 7 _ |a 0161-5505
|2 ISSN
024 7 _ |a 1535-5667
|2 ISSN
024 7 _ |a 2159-662X
|2 ISSN
024 7 _ |a altmetric:181362085
|2 altmetric
037 _ _ |a DKFZ-2025-01894
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ebner, Ricarda
|b 0
245 _ _ |a Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas.
260 _ _ |a New York, NY
|c 2025
|b Soc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1757681953_19957
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a The aim of this retrospective study was to evaluate the correlation between findings from somatostatin receptor (SSTR) PET/CT and histopathology in patients with suspected intracranial meningiomas. Methods: We conducted a retrospective analysis of 8,077 SSTR imaging studies recorded in our institutional database between 2006 and 2021. In total, 223 SSTR PET/CT scans were performed for suspected meningioma, and 240 lesions were matched with histopathology results within 4 mo. Reports from SSTR PET/CT scans and histopathology were retrospectively reviewed to assess the presence of intracranial meningiomas. The positive and negative predictive values, sensitivity, specificity, and overall diagnostic accuracy of SSTR PET/CT were calculated. The SUVmax, SUVmean, and SUVpeak were determined for each lesion. Results: In 222 (92.5%) of 240 lesions, meningioma was accurately identified by SSTR PET/CT and confirmed by histopathology. In 7 cases (2.9%), SSTR PET/CT suspected meningioma was not confirmed by histopathology (false-positive). Furthermore, in 11 cases (5%), meningioma was neither suspected by SSTR PET/CT nor confirmed by histopathology (true-negative result). There were no false-negative findings in our cohort. SSTR PET/CT demonstrated a sensitivity of 100% (95% CI, 98.4%-100%) and a specificity of 61.1% (95% CI, 35.8%-82.7%) in detecting meningiomas. Positive predictive value was 96.9% (95% CI, 93.8%-98.8%), and negative predictive value was 100% (95% CI, 71.5%-100%). The overall diagnostic accuracy was 97.1%. The receiver-operating-characteristic analysis for SUVmax in predicting histopathology results showed an area under the curve of 94%, indicating an excellent ability of SUVmax to distinguish between positive and negative histopathologic findings. Conclusion: SSTR PET/CT is a precise imaging modality for detecting intracranial meningiomas, as demonstrated by its high sensitivity. However, in 2.9% of cases, despite a positive PET/CT result, histopathology did not confirm the presence of a meningioma. Integration of MRI, histopathology, and SSTR PET/CT supports informed treatment decisions.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a PET
|2 Other
650 _ 7 |a histopathology
|2 Other
650 _ 7 |a magnetic resonance imaging
|2 Other
650 _ 7 |a meningioma
|2 Other
650 _ 7 |a somatostatin receptor
|2 Other
700 1 _ |a Braach, Jana
|b 1
700 1 _ |a Rübenthaler, Johannes
|b 2
700 1 _ |a Cyran, Clemens C
|b 3
700 1 _ |a Sheikh, Gabriel T
|b 4
700 1 _ |a Brendel, Mattias
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Albert, Nathalie L
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Tiling, Reinhold
|b 7
700 1 _ |a Greve, Tobias
|b 8
700 1 _ |a Hinterberger, Anna
|b 9
700 1 _ |a Fabritius, Matthias P
|b 10
700 1 _ |a Fink, Nicola
|b 11
700 1 _ |a Ricke, Jens
|b 12
700 1 _ |a Werner, Rudolf A
|b 13
700 1 _ |a Grawe, Freba
|b 14
773 _ _ |a 10.2967/jnumed.125.270115
|g p. jnumed.125.270115 -
|0 PERI:(DE-600)2040222-3
|p nn
|t Journal of nuclear medicine
|v nn
|y 2025
|x 0097-9058
909 C O |o oai:inrepo02.dkfz.de:304506
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NUCL MED : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-01
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NUCL MED : 2022
|d 2025-01-01
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK Koordinierungsstelle München
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21